에 대한 최신 뉴스 Humana (NYSE:HUM) 주식

Humana

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Analyst Color

Earnings Beats

Large Cap

News

Guidance

Health Care

Analyst Ratings

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

미국의 의료 보험 회사 휴매나(NYSE:HUM)의 주식은 수요일 소폭 상승 마감했다. 화요일 이 회사는 4분기 조정 주당순이익이 2.16달러 손실이라고 발표했다. 이는 전년 대비 11센트 감소한 수치로, 컨센서스와 일치하며 별 등급제에 대한 추가 투자를 포함한 것이다.

휴매나의 2025 전망, 산업 압박에도 불구하고 조심스러운 낙관론을 보여

Movers

월요일(13일) CVS 헬스(NYSE:CVS), 휴매나(NYSE:HUM) 및 유나이티드헬스(NYSE:UNH) 주가가 급등했다. 알아야 할 내용은 다음과 같다.

월요일에 급등한 CVS, 휴매나 및 유나이티드헬스, 무슨 일일까?

Equities

Government

Politics

Markets

월스트리트는 목요일에 정부 셧다운을 막으려는 시도가 실패한 후 금요일에 워싱턴 D.C.에서의 발전을 주시하고 있다. 일부 주식은 하루가 지나고 자정 마감 시한이 다가오면서 불안한 모습을 보이고 있다. 무슨 일이 있었나: 하원은 마이크 존슨(공화당-루이지애나) 하원의장이 제안한 비상 계획을 투표 몇 시간 만에 거부했다. 이 제안은 필요한 2/3의 찬성을 얻지 못했다.

美 정부 폐쇄 위협: 협상이 실패하면 휴가 여행 및 급여 지연 가능성 대두

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Hua Medicine

Humm Group Ltd

Humble Energy Inc

HUMMINGBIRD RES LTD ORD by Hummingbird Resources Ltd

Hummingbird Resources PLC

Humatech Inc

WIIM

Shares of health insurers are trading lower. Weakness in the sector may be in sympathy with UnitedHealth, which fell on reports of a DOJ investigation into Medicare billing practices.

JP Morgan analyst Lisa Gill maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $257 to $256.

Price Target

JP Morgan Maintains Neutral on Humana, Lowers Price Target to $256

Humana's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) short percent of float has fallen 11.4% since its last report. The company recently reported that it has 4.58 million shares sold short, which is 3.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Humana Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739802617_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Humana has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Humana's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Humana's peer group average for short interest as a percentage of float is 4.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Humana's Recent Short Interest

Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 16 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 75% leaning bullish and 18% bearish. Among these notable options, 14 are puts, totaling $579,028, and 2 are calls, amounting to $283,180.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $320.0 for Humana over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $230.0 to $320.0 over the preceding 30 days.
<h3>Humana Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739466037_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/28/25</td>
<td>$7.9</td>
<td>$6.6</td>
<td>$7.9</td>
<td>$260.00</td>
<td>$197.5K</td>
<td align="right">69</td>
<td align="right">250</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$48.9</td>
<td>$47.6</td>
<td>$47.6</td>
<td>$250.00</td>
<td>$85.6K</td>
<td align="right">448</td>
<td align="right">18</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.9</td>
<td>$6.4</td>
<td>$6.8</td>
<td>$257.50</td>
<td>$83.6K</td>
<td align="right">86</td>
<td align="right">125</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$22.8</td>
<td>$22.5</td>
<td>$22.5</td>
<td>$250.00</td>
<td>$49.5K</td>
<td align="right">131</td>
<td align="right">22</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$26.0</td>
<td>$22.5</td>
<td>$22.7</td>
<td>$250.00</td>
<td>$45.4K</td>
<td align="right">131</td>
<td align="right">179</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
After a thorough review of the options trading surrounding Humana, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Humana</h3>
<ul>
<li>Trading volume stands at 334,823, with HUM's price down by -1.33%, positioned at $256.57.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $277.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Humana with a target price of $288. 
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $283. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Humana with a target price of $270. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $290. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Humana, maintaining a target price of $255. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Humana, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Check Out What Whales Are Doing With HUM

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and raises the price target from $255 to $270.

Barclays Maintains Equal-Weight on Humana, Raises Price Target to $270

Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare Advantage members in Alabama, Louisiana, Mississippi, Tennessee, and now Georgia with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) will have access to Monogram's evidence-based nephrology and multispecialty value-based care in the comfort of their homes.

Biotech

Humana And Monogram Health Announce Expansion To Provide In-Home Kidney Care For Medicare Advantage Members In Alabama, Louisiana, Mississippi, Tennessee, And Georgia

On Tuesday, Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted a fourth-quarter adjusted earnings per share loss of $2.16. That&#8217;s down from 11 cents a year ago, <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">in line with the consensus</a> and including <a href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" target="_blank" rel="noreferrer noopener">incremental investments in Stars</a>.
The company reported revenues of $29.19 billion, up 13.5% year-over-year from $25.73 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/02/43621782/insurance-giant-humanas-q4-earnings-at-par-with-estimates-2025-profit-outlook-falls-below-street-view" rel="noreferrer noopener">consensus of $28.84 billion</a>.
For 2025, Humana expects its insurance segment's benefit ratio guidance of approximately 90.1-90.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
Cantor Fitzgerald expects a more cautious approach to cost trend assumptions. However, analysts Sarah James and Gabie Ingoglia acknowledge the reasoning behind expecting some moderation.
&#8220;We have incremental concerns over outlier assumptions on cost trends though find some logic in the rationale, and we believe the Street may be underestimating the earnings power in turning around the group MA book in &#8217;26 and &#8217;27, which we estimate could represent a $1-2 earnings drag to 2025,&#8221; the analysts wrote.
Humana stands out by projecting a slowdown in the 2025 cost trend to the mid-single digits compared to the high-single digits in 2024. This contrasts with UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Elevance Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), and Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), which anticipate continued elevated trends from 2024.
Humana attributes the expected slowdown to factors that won't repeat in 2025, such as the impact of the &#8220;two-midnight&#8221; rule, though it still expects high specialty drug costs. The company also noted stable cost trends from Q3 to Q4 2024, except for seasonal increases in supplemental benefits that drive year-end utilization.
Management plans to aggressively cut costs and AEP results confirm the company&#8217;s pricing strategy is working, analysts say. However, the company lost about 30,000 D-SNP members due to redetermination.
Another positive is that the PDP pricing strategy isn't facing issues.
Price Action: Humana stock is up 0.80% at $259.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43662901/why-is-nano-cap-cancer-focused-xilio-therapeutics-stock-trading-over-100-on-wednesday" target="_blank" rel="noreferrer noopener">Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?</a></li>
</ul>
Image: Shutterstock

Humana 2025 Outlook Shows Cautious Optimism Despite Industry Pressures

In the last three months, 7 analysts have published ratings on Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $284.57, a high estimate of $301.00, and a low estimate of $255.00. Observing a 2.41% increase, the current average has risen from the previous average price target of $277.86. 
<img src="https://www.benzinga.com/files/images/story/2025/1739383265_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$283.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$285.00</td>
<td>$301.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$255.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$288.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$290.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Erin Wright</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$301.00</td>
<td>$288.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Humana's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Humana's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Humana analyst ratings.</a>
<h2>About Humana</h2>
Humana is one of the largest private health insurers in the us with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Humana's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.26% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Humana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.8% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 0.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio stands notably higher than the industry average, reaching 0.74. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Humana Stock: Analyst Perspectives (7 Ratings)

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$48.6K</td>
<td>44.4K</td>
<td>7.2K</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$157.6K</td>
<td>109</td>
<td>1.9K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$28.5K</td>
<td>2.8K</td>
<td>840</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$180.00</td>
<td>$43.0K</td>
<td>1.4K</td>
<td>316</td>
</tr>
<tr>
<td>EBS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.00</td>
<td>$43.8K</td>
<td>4</td>
<td>200</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$65.00</td>
<td>$29.2K</td>
<td>1.3K</td>
<td>159</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$245.00</td>
<td>$191.7K</td>
<td>141</td>
<td>125</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$37.00</td>
<td>$69.7K</td>
<td>1.0K</td>
<td>87</td>
</tr>
<tr>
<td>EXEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$17.00</td>
<td>$29.5K</td>
<td>98</td>
<td>50</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$800.00</td>
<td>$37.5K</td>
<td>843</td>
<td>31</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 37 day(s) on March 21, 2025. This event was a transfer of 2561 contract(s) at a $27.50 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $48.6K, with a price of $19.0 per contract. There were 44426 open contracts at this strike prior to today, and today 7236 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option sweep that happens to be bullish, expiring in 128 day(s) on June 20, 2025. This event was a transfer of 901 contract(s) at a $20.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $157.6K, with a price of $175.0 per contract. There were 109 open contracts at this strike prior to today, and today 1920 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 20 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $28.5K, with a price of $1425.0 per contract. There were 2849 open contracts at this strike prior to today, and today 840 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 200 contract(s) at a $180.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $215.0 per contract. There were 1473 open contracts at this strike prior to today, and today 316 contract(s) were bought and sold. 
• Regarding EBS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), we observe a call option trade with bearish sentiment. It expires in 219 day(s) on September 19, 2025. Parties traded 200 contract(s) at a $11.00 strike. The total cost received by the writing party (or parties) was $43.8K, with a price of $219.0 per contract. There were 4 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $195.0 per contract. There were 1333 open contracts at this strike prior to today, and today 159 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 65 contract(s) at a $245.00 strike. The total cost received by the writing party (or parties) was $191.7K, with a price of $2950.0 per contract. There were 141 open contracts at this strike prior to today, and today 125 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bullish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 81 contract(s) at a $37.00 strike. The total cost received by the writing party (or parties) was $69.7K, with a price of $861.0 per contract. There were 1026 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we notice a call option trade that happens to be neutral, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 18 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $29.5K, with a price of $1640.0 per contract. There were 98 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 5 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $7518.0 per contract. There were 843 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

BMRN

EXEL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

10 Health Care Stocks With Whale Alerts In Today's Session

RBC Capital analyst Ben Hendrix reiterates Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Outperform and maintains $283 price target.

Reiteration

RBC Capital Reiterates Outperform on Humana, Maintains $283 Price Target

Cantor Fitzgerald analyst Sarah James reiterates Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and maintains $290 price target.

Cantor Fitzgerald Reiterates Neutral on Humana, Maintains $290 Price Target

Morgan Stanley analyst Erin Wright maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $301 to $285.

Morgan Stanley Maintains Equal-Weight on Humana, Lowers Price Target to $285

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has outperformed the market over the past 20 years by 2.35% on an annualized basis producing an average annual return of 10.76%. Currently, Humana has a market capitalization of $30.99 billion. 
Buying $100 In HUM: If an investor had bought $100 of HUM stock 20 years ago, it would be worth $764.30 today based on a price of $257.34 for HUM at the time of writing.
<h3>Humana's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739317568_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Humana Stock In The Last 20 Years

U.S. stocks edged marginally lower on Tuesday after Federal Reserve Chair Jerome Powell reiterated that the central bank is in no hurry to cut interest rates during his testimony before the Senate Banking Committee, offering little <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43628752/feds-powell-reiterates-no-hurry-to-cut-interest-rates-as-inflation-remains-somewhat-elevated">support for risk assets.</a>
Investors remained on edge ahead of Wednesday's key inflation report, with the Bureau of Labor Statistics set to release the January Consumer Price Index.
The S&amp;P 500 dipped 0.1%, the Nasdaq 100 declined 0.2%, and small-cap stocks underperformed. Bucking the trend, the Dow Jones Industrial Average posted a marginal 0.1% gain.
Company-wise, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) surged 7%, after Vice President J.D. Vance indicated that artificial intelligence chips will be manufactured in the U.S.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell by over 4%, reaching the lowest levels in eleven weeks, pressured by weak January auto sales in China.
Geopolitical tensions flared as the European Union threatened countermeasures in response to President Donald Trump's announcement of 25% tariffs on aluminum and steel.
Long-dated Treasury yields moved higher, with the 10-year yield rising to 4.54%. Yet, the broader dollar index – as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – weakened, down 0.2%. 
Gold paused for a breather, remaining flat at $2,900 per ounce. Oil prices inched up by 1%, eyeing the third straight session of gains. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) weakened 1.3% to $96,000. 
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,526.92</td>
<td>0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,064.30</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,714.53</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,273.29</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:35 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.1% down to $604.07.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.1% up to $445.06.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.3% to $527.55.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.7% to $225.34.</li>
<li>The&nbsp;Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 1.4%; the&nbsp;Consumer Discretionary Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
<ul>
<li>Steel Dynamics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) rose 2.4% after KeyBanc raised the stock to Overweight.</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) surged 5% after Elliott Investment Management urged the company to sell or spin off its midstream business, estimating its value at over $40 billion.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) gained 2.8%, and Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) climbed 2% amid speculation about a potential AI partnership for iPhone users in China.</li>
</ul>
Stocks reacting to earnings reports include: 
<ul>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>): up 3.8%</li>
<li>Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>): up 7.5%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>): up 3.7%</li>
<li>DuPont de Nemours Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>): up 7.8%</li>
<li>Marriott International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>): down 5.6%</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>): down 6.5%</li>
<li>Masco Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>): up 0.6%</li>
<li>WK Kellogg Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>): down 0.7%</li>
<li>Arvinas Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>): down 6.3%</li>
<li>AutoNation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>): down 3.3%</li>
<li>Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>): down 4.7%</li>
<li>Carrier Global Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 1.8%</li>
<li>Fidelity National Information Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>): down 14.9%</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>): up 6.2%</li>
<li>IPG Photonics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>): down 5.9%</li>
<li>LCI Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>): up 3.5%</li>
<li>Leidos Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>): down 5.4%</li>
<li>MYT Netherlands Parent BV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>): up 19.4%</li>
<li>NNN REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>): up 5.8%</li>
<li>Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>): up 1.4%</li>
<li>Sunoco LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>): down 1.8%</li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>): down 3.5%</li>
<li>USA Compression Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>): down 2.9%</li>
<li>Wesco International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>): up 2.1%</li>
</ul>
Companies reporting after the close include:
<ul>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>)</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</li>
<li>Welltower Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>)</li>
<li>Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>)</li>
<li>Primerica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>)</li>
<li>Allison Transmission Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>)</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>)</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>)</li>
<li>Brighthouse Financial Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>)</li>
<li>DoorDash Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NYSE">DASH</a>)</li>
<li>W. P. Carey Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>)</li>
<li>Agree Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>)</li>
<li>Red Rock Resorts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>)</li>
<li>Teradata Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>)</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43632327/steel-stocks-breakout-analyst-sees-bullish-setup-for-us-steel-nucor-steel-dynamics">Tariffs Drive Steel Stock Gains As Analyst Highlights Catalysts For Nucor, US Steel</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

ETFs

$BTC

AAPL

ALSN

ARVN

BABA

Brighthouse Financial, Inc. - Common Stock

CARR

DASH

SPDR Dow Jones Industrial Average ETF Trust

GILD

INTC

IPGP

LCII

LDOS

MYTE

RPRX

SPGI

STLD

TSLA

USAC

PowerShares DB US Dollar Index Bullish Fund

WELL

Select Sector SPDR-Consumer Discretionary

US Stocks Dip As Powell Stays Cautious, Intel Climbs, Tesla Sinks To 11-Week Low: What's Driving Markets Tuesday?

Humana shares are trading lower following soft 2025 EPS guidance.

On Tuesday, Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) posted a fourth-quarter adjusted EPS loss of $(2.16), down from $(0.11) a year ago, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">in line with the consensus</a> and including <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" rel="noreferrer noopener">incremental investments in Stars</a>.
The company reported revenues of $29.19 billion, up 13.5% year-over-year from $25.73 billion, beating the&nbsp;consensus of $28.84 billion, primarily driven by higher per-member Medicare premiums and Medicare Advantage and state-based <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43618108/humana-reports-fourth-quarter-2024-financial-results-provides-full-year-2025-financial-guidance" rel="noreferrer noopener">contracts membership growth</a>, offset by a decline in stand-alone PDP membership, and a decline in membership in the group commercial medical business as a result of the company&#8217;s decision to exit the business.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" rel="noreferrer noopener">RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders</a>
Humana&nbsp;ended the fourth quarter with 16.35 million in total medical membership, compared to 16.86 million a year ago. Individual Medicare Advantage membership&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/5334c95b-ebc7-41d7-bc1b-2c2a325606dd" rel="noreferrer noopener">reached</a> 5.66 million, up from 5.67 million a year ago.
Humana <a target="_blank" href="https://humana.gcs-web.com/static-files/fd6f79ca-bbaf-4401-b3e3-594ed340ec68" rel="noreferrer noopener">says</a> the insurance segment adjusted benefit ratio of 91.9%, which includes a 20-basis point increase related to incremental Star Ratings investments, was consistent with expectations.
Guidance: Humana expects 2025 GAAP sales of $126 billion-$128 billion versus the consensus of $119.41 billion.
Sales guidance includes Insurance segment sales of $121 billion—$123 billion and CenterWell segment sales of $20.5 billion—$21.5 billion.
The insurer expects individual Medicare Advantage annual membership decline of approximately 550,000, or approximately 10%, from 2024, inclusive of the company&#8217;s decision to exit certain unprofitable plans and counties, with group Medicare Advantage to remain relatively flat and Medicare stand-alone PDP growth of approximately 200,000.
Humana reaffirms the 2025 adjusted EPS outlook of $16.25 versus the consensus of $16.71.
For 2025, Humana expects its insurance segment&#8217;s benefit ratio guidance of approximately 90.1-90.5%.
In prepared remarks, Humana <a target="_blank" href="https://humana.gcs-web.com/static-files/fd6f79ca-bbaf-4401-b3e3-594ed340ec68" rel="noreferrer noopener">said</a>, &#8220;Our 2025 MA pricing strategy was focused on resetting pricing and membership to more accurately reflect the funding and medical cost trend environment, improving underlying margins.&#8221;
Price Action: HUM stock is up 3.07% at $274.99 during the premarket session on last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43604305/what-to-expect-when-biotech-giant-gilead-reports-q4-earnings-on-tuesday" target="_blank" rel="noreferrer noopener">What To Expect When Biotech Giant Gilead Reports Q4 Earnings On Tuesday?</a></li>
</ul>
Photo: T. Schneider via Shutterstock

Earnings

Insurance Giant Humana's Q4 Earnings: 13% Revenue Growth, 2025 Profit Outlook Falls Below Street View

Humana shares are trading higher after following a Q4 revenue beat.

Humana Reaffirms 2025 Adjusted EPS Of Around $16.25 Versus Consensus Of $16.71

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) reported quarterly losses of $(2.16) per share which met the analyst consensus estimate. This is a 1863.64 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $29.199 billion which beat the analyst consensus estimate of $28.837 billion by 1.25 percent. This is a 13.46 percent increase over sales of $25.734 billion the same period last year.

Humana Q4 2024 Adj. EPS $(2.16), Inline, Sales $29.199B Beat $28.837B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is estimated to report quarterly earnings at $1.05 per share on revenue of $743.60 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is likely to report quarterly earnings at $4.26 per share on revenue of $6.81 billion. 
• Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is estimated to report quarterly loss at $2.12 per share on revenue of $28.84 billion. 
• Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $5.20 billion. 
• DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is projected to report quarterly earnings at $0.98 per share on revenue of $3.07 billion. 
• BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $45.65 billion. 
• Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $15.02 million. 
• NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $217.60 million. 
• OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $48.93 million. 
• Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) is estimated to report quarterly loss at $1.04 per share on revenue of $59.49 million. 
• Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is expected to report quarterly loss at $0.01 per share on revenue of $26.52 million. 
• Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $37.65 million. 
• Ceragon Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $105.16 million. 
• SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $202.91 million. 
• Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $28.88 million. 
• IPG Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $229.47 million. 
• LCI Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $799.81 million. 
• Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) is likely to report quarterly loss at $0.07 per share on revenue of $10.50 million. 
• Sunoco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $5.92 billion. 
• WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $650.00 million. 
• Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $2.63 billion. 
• Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) is likely to report quarterly earnings at $2.36 per share on revenue of $6.39 billion. 
• MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $217.77 million. 
• Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $2.73 billion. 
• WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $5.42 billion. 
• TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $463.18 million. 
• USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $242.95 million. 
• S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is projected to report quarterly earnings at $3.41 per share on revenue of $3.46 billion. 
• Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $10.70 billion. 
• Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) is projected to report quarterly earnings at $2.27 per share on revenue of $4.13 billion. 
• Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $1.84 billion. 
• GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $1.83 billion. 
• Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) is expected to report quarterly earnings at $1.81 per share on revenue of $4.03 billion. 
<h3>Companies Reporting After The Bell</h3>
• Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is likely to report quarterly earnings at $1.70 per share on revenue of $7.15 billion. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is projected to report quarterly earnings at $1.06 per share on revenue of $129.03 million. 
• Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) is projected to report quarterly loss at $1.03 per share on revenue of $2.73 billion. 
• Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is projected to report quarterly loss at $0.07 per share on revenue of $30.83 million. 
• Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $1.49 billion. 
• Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $5.78 billion. 
• Evolution Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EPM#AMEX">EPM</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $22.73 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $144.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.16 per share on revenue of $6.59 million. 
• Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) is expected to report earnings for its fourth quarter. 
• United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $327.70 million. 
• Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $15.62 million. 
• HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $28.48 million. 
• Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is likely to report quarterly loss at $0.14 per share on revenue of $500 thousand. 
• Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is projected to report quarterly loss at $1.38 per share on revenue of $14.11 million. 
• Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $562.72 million. 
• Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $106.25 million. 
• BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $168.10 million. 
• Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) is likely to report quarterly earnings at $4.90 per share on revenue of $766.63 million. 
• Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) is likely to report quarterly earnings at $1.91 per share on revenue of $765.40 million. 
• Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $15.30 million. 
• W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $397.32 million. 
• Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $883.43 million. 
• Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $509.65 million. 
• America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $12.27 billion. 
• Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $3.13 billion. 
• Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) is expected to report quarterly loss at $0.24 per share on revenue of $45.84 million. 
• Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) is expected to report quarterly loss at $0.61 per share on revenue of $1.88 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $934.31 million. 
• Mercury General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $1.23 billion. 
• American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) is expected to report quarterly earnings at $1.53 per share on revenue of $6.70 billion. 
• Diodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $337.10 million. 
• Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) is projected to report quarterly loss at $0.01 per share on revenue of $1.55 billion. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $532.04 million. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $533.26 million. 
• Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $417.67 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $85.54 million. 
• Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $65.48 million. 
• OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $128.13 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $245.02 million. 
• Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $181.92 million. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $2.12 billion. 
• Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $80.90 million. 
• Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $209.12 million. 
• Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $24.40 million. 
• InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $71.16 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $254.21 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $21.43 million. 
• Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $491.36 million. 
• Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) is likely to report quarterly earnings at $3.51 per share on revenue of $3.08 billion. 
• Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $83.33 million. 
• Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) is estimated to report quarterly earnings at $4.58 per share on revenue of $2.22 billion. 
• Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $203.87 million. 
• Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $189.30 million. 
• DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $2.84 billion. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is projected to report quarterly earnings at $1.03 per share on revenue of $156.13 million. 
• Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $256.84 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPT

ANGI

ATEX

ATOM

BIOX

CFLT

CRNT

CURB

DIOD

ELMD

FORR

FRSH

GLAD

GNSS

HIVE

JRSH

LYFT

MCRI

OESX

SAGE

SHOP

SMCI

SMWB

SQNS

TYGO

UFCS

UPST

YTRA

Earnings Scheduled For February 11, 2025

Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Humana Inc. - HUM

Press Releases

Value-Based Care Simplifies Healthcare for Patients and Clinicians, New Report Finds

Humana Reports Fourth Quarter 2024 Financial Results; Provides Full Year 2025 Financial Guidance

NYSE: HUM Lawsuit Update: Investors who lost money with Humana Inc. (NYSE: HUM) shares should contact the Shareholders Foundation

Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program

CenterWell Poised for Further Primary Care Expansion in 2025

Humana Board Declares Payment of Quarterly Dividend to Stockholders

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments

Centene

Elevance Health

HealthEquity

Molina Healthcare

NeueHealth

Progyny

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group

JP Morgan

Barclays

RBC Capital

Cantor Fitzgerald

Morgan Stanley

미국의 의료 보험 회사 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)의 주식은 수요일 소폭 상승 마감했다. 화요일 이 회사는 4분기 조정 주당순이익이 2.16달러 손실이라고 발표했다. 이는 전년 대비 11센트 감소한 수치로, <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">컨센서스와 일치</a>하며 <a href="https://www.benzinga.com/government/regulations/25/01/43173248/us-health-agency-cms-to-appeal-medicare-star-ratings-recalculation-ruling" target="_blank" rel="noreferrer noopener">별 등급제에 대한 추가 투자</a>를 포함한 것이다.
이 회사는 매출이 291억 9천만 달러로, 전년 대비 257억 3천만 달러에서 13.5% 증가하여 <a href="https://www.benzinga.com/25/02/43621782/insurance-giant-humanas-q4-earnings-at-par-with-estimates-2025-profit-outlook-falls-below-street-view" target="_blank" rel="noreferrer noopener">컨센서스 288억 4천만 달러</a>를 초과했다고 보고했다.
휴매나는 2025년 보험 부문의 손익 비율 가이던스를 약 90.1-90.5%로 예상하고 있다.
또한 읽어보기: <a href="https://www.benzinga.com/general/health-care/25/01/43321236/rfk-jr-and-big-pharma-stocks-to-watch-as-health-secretary-hopeful-answers-pointed-questions-on-drugs-insurance-trump-exec-orders" target="_blank" rel="noreferrer noopener">RFK Jr.와 대제약사: 보건부 장관 후보가 약물, 보험, 트럼프 행정명령에 대한 날카로운 질문에 답변</a>
캔터 피츠제럴드는 비용 추세 가정에 대해 보다 신중한 접근을 예상한다. 그러나 애널리스트인 사라 제임스(Sarah James)와 가비 잉골리아(Gabie Ingoglia)는 일부 조정이 필요하다는 논리에는 동의한다.
&#8220;우리는 비용 추세에 대한 이례적인 가정에 대해 우려를 가지고 있으나, 그 논리에는 일정 부분 타당성이 있다고 생각한다. 또한, 시장이 2026년과 2027년에 그룹 MA 상품을 회복하는 데 있어 이익 잠재력을 과소평가하고 있을 수 있다고 믿고 있다. 이는 2025년에는 $1-2의 이익 감소 요인으로 작용할 수 있다&#8221;라고 이 애널리스트들이 언급했다.
휴매나는 2025년 비용 추세가 중간 단일 자릿수로 둔화될 것으로 예상하는 점에서 두드러진다. 이는 2024년의 높은 단일 자릿수와 대조적이다. 반면, 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), 엘레반스 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) 및 몰리나 헬스케어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)는 2024년부터 계속해서 높은 추세가 유지될 것으로 예상하고 있다.
휴매나는 2025년에는 반복되지 않을 요인, 즉 &#8220;두 자정&#8221; 규정의 영향을 기대하며, 여전히 높은 전문 약품 비용을 예상하고 있다. 이 회사는 또한 2024년 3분기에서 4분기까지 안정적인 비용 추세가 유지되지만, 연말 이용률을 증가시키는 보충 혜택의 계절적 증가가 있다고 언급했다.
경영진은 비용을 공격적으로 절감할 계획이며, AEP 결과는 회사의 가격 책정 전략이 효과를 보고 있음을 확인한다. 그러나 이 회사는 재심사로 인해 약 30,000명의 D-SNP 회원을 잃었다.
또 다른 긍정적인 점은 PDP 가격 책정 전략이 문제에 직면하지 않고 있다는 것이다.
가격 동향: 휴매나의 주식은 수요일 0.76% 상승 260.03달러에 마감되었다.
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43662901/why-is-nano-cap-cancer-focused-xilio-therapeutics-stock-trading-over-100-on-wednesday" target="_blank" rel="noreferrer noopener">왜 나노-캡 암 중심의 자일리오 테라퓨틱스 주식이 수요일에 100% 이상 거래되고 있나요?</a></li>
</ul>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일(13일) CVS 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), 휴매나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) 및 유나이티드헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) 주가가 급등했다. <a href="//www.benzinga.com//node/42953047"" target="_blank" rel="noopener">알아야 할 내용은 다음과 같다.</a>
알아야 할 내용: 미국 메디케어 메디케이드 서비스센터(CMS)가 메디케어 어드밴티지 지급액 인상을 제안한 후 건강 보험 회사들의 주가가 상승하고 있다.
<a href="//www.bloomberg.com/news/articles/2025-01-10/us-proposes-21-billion-boost-to-insurers-for-medicare-payments?embedded-checkout=true"" target="_blank" rel="noopener">블룸버그</a> 통신에 따르면 메디케어 어드밴티지 플랜의 보험료를 평균 4.3% 인상할 것을 제안했으며, 계획이 채택되면 2026년에 예상되는 2025년 수치에 비해 210억 달러가 추가로 지급될 수 있다. 이는 현재의 보험 요율이 의료비를 감당하기에는 너무 낮다는 의료 보험사들의 우려에 따른 것이다.
JP모건 애널리스트 리사 길은 블룸버그와의 인터뷰에서 "최근 몇 년간 메디케어 보험사들은 요율이 불충분하다고 생각해 왔다"면서도 "트럼프의 CMS 하에서 요율이 개선될 수 있다는 낙관론이 있다"고 말했다.
메디케어 어드밴티지 플랜을 제공하는 건강 보험 회사는 연방 정부로부터 수혜자에게 직접 보험금을 지급받는다. 이러한 지급액이 증가하면 수익이 증가하고 마진이 개선되어 해당 기업에 대한 투자자의 신뢰가 높아질 수 있다.
특히, KFF의 보고에 따르면 2024년에 CVS, 휴매나, 유나이티드헬스가 메디케어 어드밴티지 플랜의 절반 이상을 판매한 것으로 나타났다. 또한 메디케어 지불 자문위원회는 2023년에 메디케어 어드밴티지가 메디케어 수혜자의 절반 이상을 커버했다고 언급했다.
미국은 향후 10년간 민간 메디케어 플랜에 대한 지불금으로 9조 2,000억 달러를 지출할 것으로 예상된다.
주가 움직임: <a href=""https://www.benzinga.com/pro/"">벤징가 프로</a> 데이터에 따르면 월요일 CVS 주식은 7.31% 상승한 51.52달러, 휴매나 주식은 6.77% 상승한 287.36달러, 유나이티드헬스 주식은 3.93% 상승한 541.14달러를 기록했다.
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월스트리트는 <a href="https://www.benzinga.com/24/12/42607744/house-rejects-trump-endorsed-backup-plan-to-prevent-government-shutdown-and-suspend-debt-limit-lawmakers-chant-he" target="_blank" rel="noopener" data-google-interstitial="false">목요일에 정부 셧다운을 막으려는 시도가 실패한</a> 후 금요일에 워싱턴 D.C.에서의 발전을 주시하고 있다. 일부 주식은 하루가 지나고 자정 마감 시한이 다가오면서 불안한 모습을 보이고 있다.
무슨 일이 있었나: 하원은 마이크 존슨(공화당-루이지애나) 하원의장이 제안한 비상 계획을 투표 몇 시간 만에 거부했다. 이 제안은 필요한 2/3의 찬성을 얻지 못했다.
도널드 트럼프 대통령 당선인의 지원을 받은 이 자금 지원 법안은 2년간의 부채 한도 면제를 포함하여 주로 민주당으로부터 반대에 부딪혔다. 이 법안은 정부 자금 지원을 기존 수준으로 3월 중순까지 유지하고, 부채 한도를 2년간 연기하며, 약 1,000억 달러의 재난 구호 기금과 약 100억 달러의 농민 경제 지원 기금을 배정하는 내용이었다.
<h2 class="wp-block-heading">시장 움직임 및 영향을 받은 부문</h2>
방산 섹터: 록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), 노스롭 그루먼(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) 및 L3해리스 테크놀로지스s(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>)와 같은 방산업체들은 정부 계약에 크게 의존한다. 셧다운이 발생하면 계약 수주와 지급이 지연될 수 있어 현금 흐름과 주가에 영향을 미칠 수 있다.
헬스케어 섹터: 메디케어와 메디케이드와 같은 정부 건강 프로그램에서 상당한 매출을 올리는 회사들은 셧다운 동안 지급 지연을 겪을 수 있다. 이는 유나이티드헬스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)과 휴마나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>)와 같은 회사들에 영향을 미칠 수 있다.
항공우주 섹터: 연방 계약이나 규제 승인을 의존하는 항공우주 회사들은 지연에 직면할 수 있으며, 이는 운영과 주가에 영향을 미칠 수 있다. 이러한 주식으로는 록히드 마틴과 보잉(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)이 포함된다.
소비재 및 소매 섹터: 셧다운은 연방 직원의 휴직으로 이어져 급여 지급이 지연될 수 있다. 이는 가처분 소득 감소로 이어져 소비자 지출이 줄어들어 소매업체와 소비재 제조업체들에 부정적인 영향을 미칠 수 있다.
금융 섹터: 정부 셧다운은 경제 보고서와 데이터 발표를 지연시켜 금융 시장에 불확실성을 초래할 수 있다. 이 불확실성은 시장 변동성을 증가시켜 금융 기관들과 투자 회사들에 영향을 미칠 수 있습.
<h2 class="wp-block-heading">휴가 여행객들 주의하세요</h2>
바쁜 휴가 시즌이 다가오고 교통안전청(TSA)는 향후 몇 주 동안 4천만 명의 공항 여행객을 검색할 것으로 예상하는 가운데, 항공 교통 관제사들고와 필수 공항 직원들은 급여 없이 일을 할 수도 있다.
셧다운이 임박하기 전에 AAA는 1억 1천 9백만 명이 휴가를 맞아 도로에 나설 것으로 예측했다고 뉴욕 타임스가 <a href="https://www.nytimes.com/2024/12/20/travel/government-shutdown-travel.html" target="_blank" rel="noopener">언급</a>했다. 자정까지 해결책이 마련되지 않으면 이미 혼잡한 고속도로는 항공기와 기차가 만석이 되거나, 더 나쁘게는 취소되는 상황으로 인해 더욱 혼잡해질 수 있다. D.C.에서 무슨 일이 발생하든, 암트랙(Amtrak)은 기차를 정시에 운행할 것으로 예상된다.

지금 읽어야 할 것:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42619788/market-volatility-halts-on-soft-inflation-data-yet-traders-remain-wary-of-fighting-the-fed-10-etfs-moving-friday">약한 인플레이션 데이터로 시장 변동성이 중단되었지만, 트레이더들은 여전히 연방준비제도에 맞서는 것을 경계하고 있습니다: 금요일에 움직이는 10개의 ETF</a></li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

<h3 class="wp-block-heading">새로이 등장한 블록</h3>
<ul>
<li>스타벅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>)가 중국 사업의 일부 지분을 매각하려고 한다. 최근 1분기 중국 내 동일 매장 매출이 14% 감소하면서, 시애틀에 본사를 둔 이 커피 소매업체는 치열한 <a href="https://www.benzinga.com/news/asset-sales/24/11/42117962/starbucks-eyes-stake-sale-in-china-amid-fierce-competition-and-falling-sales">경제적 및 경쟁적 압박</a>에 적응하기 위한 파트너십을 모색하고 있다.</li>
</ul>
<h3 class="wp-block-heading">파산 블록</h3>
<ul>
<li>스낵 제조업체 하스사이드 푸드 솔루션스(Hearthside Food Solutions)이 파산했다. 사모펀드 소속 회사는 파트너스 그룹 홀딩 AG(Partners Group Holding AG)와 찰스뱅크 캐피털 파트너스(Charlesbank Capital Partners)의 소유 하에 쌓인 19억 달러의 부채를 정리하려고 한다. 두 회사는 하스사이드를 24억 달러 이상에 인수했다. 자산과 부채는 각각 10억 달러에서 100억 달러 사이이다. 작년에는 미국에서 파산한 사모펀드 포트폴리오 회사의 수가 <a href="https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/private-equity-portfolio-companies-on-track-for-most-bankruptcies-since-2020-74886821">2020년의 파산 건수를 초과</a>했다. 2024년이 더 나쁠지는 지켜봐야 한다.</li>
</ul>
<ul>
<li>노스볼트(Northvolt)가 58억 달러의 부채로 파산 신청을 했다. 스웨덴 배터리 제조업체인 노스볼트는 폭스바겐 AG(OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>)와 BMW AG(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMWYY#OTC">BMWYY</a>)에 배터리를 공급하며 작년에 <a href="https://www.benzinga.com/news/23/03/31506581/volkswagen-bmw-battery-supplier-northvolt-eyes-raising-5b-via-debt">부채를 조달하기 위해 은행과 협상</a>했던 기억이 있다. 이제는 미국 챕터 11 파산 보호 신청에 따라 구조조정을 희망하고 있다.</li>
</ul>
참고: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42024210/benzinga-bulls-and-bears-tesla-disney-gold-and-hedge-funds-project-bitcoin-to-hit-100k-150k">벤징가의 불스 및 베어스: 테슬라, 디즈니, 금 &#8211; 그리고 헤지펀드가 비트코인이 10만 달러에서 15만 달러에 이를 것이라고 전망</a>
<h3 class="wp-block-heading">블록에서의 업데이트</h3>
<ul>
<li>구글의 앤트로픽(Anthropic)에 대한 20억 달러 투자 계획이 <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">블룸버그</a>에 따르면 위험에 처해 있다. 앤트로픽은 제프 베이조스가 지원하는 인공지능(AI) 혁신 기업 오픈AI의 경쟁사입니다. 미국 법무부(DOJ)는 <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">수요일 법원 제출에서</a> 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)의 구글이 온라인 검색 독점을 해체하기 위해 크롬 브라우저를 매각해야 한다고 권고했다. 여기서 끝나지 않는다. 규제 당국은 구글이 소비자가 정보를 검색하는 곳을 제어하는 회사와 어떤 거래도 할 수 없도록 금지해야 한다고 말했다. <a href="https://www.benzinga.com/tech/24/11/42123646/google-anthropic-deal-in-jeopardy-as-us-justice-department-looks-to-snap-online-search-monopoly">이에는 AI 제품도 포함</a>된다.</li>
</ul>
<ul>
<li>리키 윌리엄스(Ricky Williams)의 하이즈맨(Highsman)이 대마초 브랜드 프로즌 필즈(Frozen Fields)와 합병하여 톱 시드(Top Seed Inc)를 형성했다. 이 파트너십은 대마초와 대마 산업 분야를 통합하여 제품을 <a href="https://www.benzinga.com/markets/cannabis/24/11/42097662/ricky-williams-highsman-merges-with-hemp-brand-frozen-fields">향상시키고 공급망을 통제</a>한다.</li>
</ul>
<ul>
<li>메이크마이트립(MakeMyTrip)이 하페이(Happay)를 크레드(CRED)로부터 인수했다. 이 거래는 인도에서 기업 여행 및 경비 관리 솔루션을 강화할 것으로 예상된다. 하페이의 팀은 메이크마이트립과 통합되어 <a href="https://www.benzinga.com/general/travel/24/11/42039458/makemytrip-agrees-to-acquire-happay-bolstering-its-arsenal-for-corporate-travel-solutions">900개 이상의 고객을 지원</a>할 것이다.</li>
</ul>
<ul>
<li>앰코(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>)와 베리 글로벌 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>)가 주식 거래로 합병하기로 합의했으며, 이번 거래은 베리 주식을 주당 <a href="https://www.benzinga.com/news/large-cap/24/11/42069248/amcor-and-berry-seal-the-deal-73-59-per-share-merger-to-forge-packaging-powerhouse">73.59달러로 평가</a>했다.</li>
</ul>
<ul>
<li>일본제철(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NISTF#OTC">NISTF</a>)의 경영진이 펜실베니아로 출장을 가서 US 스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)에 대한 150억 달러 인수 제안을 지지받으려 했다. 이 일본 철강 거인은 워싱턴에서 정치적 저항에 직면하고 있다. 모리 타카히로(Takahiro Mori), 일본제철의 부회장이 인수 찬성을 위해 토요일에 피츠버그에 도착했다. 이 거래는 조 바이든 대통령과 도널드 트럼프 대통령 당선자가 모두 미국 철강회사가 <a href="https://www.benzinga.com/markets/24/11/42056111/nippon-steel-execs-rally-support-in-pennsylvania-amid-pushback-on-us-steel-takeover">미국 소유로 남아있기를 선호</a>한다고 반대에 직면하고 있다.</li>
</ul>
<h3 class="wp-block-heading">블록에서의 메모</h3>
다윈 파이낸셜 컴퍼니(Darwin Financial Company)의 공동 설립자 조슈아 로빈슨(Joshua Robinson)은 INYOAG LLC와의 5,500만 달러 자금 조달 거래를 발표했다. 이 자금은 캘리포니아 이노 카운티에 있는 태양열 발전 광산 개발에 사용될 예정이며, 해당 지역에는 은, 납, 아연, 텅스텐 및 구리 매장량이 확인되어 있다. 로빈슨과의 대화 내용은 다음과 같다:
<h4 class="wp-block-heading">BZ: 다윈 금융과 기초 금속 광산업체 INYOAG 간의 거래 구조는 어떻게 되나요? </h4>
로빈슨: 이번 거래 구조는 5,500만 달러 프로젝트 자금 조달 패키지로, 세 가지 구성 요소로 나누어진다: 황화물 및 산화물 생산에 각각 1,750만 달러 및 1,250만 달러의 6년 만기 채권, 그리고 광산이 월 1,000만 달러의 매출을 달성할 경우에만 발동되는 2,000만 달러의 조건부 주식 투자이다. 우리는 두 생산 트랙에서 총 매출의 17%를 확보하며, 이는 안전한 록박스 방식으로 구조화된다. 이것은 단순한 주식 투자가 아니며, 우리는 추가적인 상승 가능성을 제공하기 위해 특별히 이렇게 설계했다.
<h4 class="wp-block-heading">추가 투자자/합작 투자 파트너를 찾고 있나요? </h4>
네, 우리는 이것을 여러 층의 상승 가능성을 창출하기 위해 고의적으로 구조화했다. 이는 광산 분야에서 꽤 독특한 접근 방식이다. 우리는 생산에서의 단기 현금 흐름과 상당한 확장 가능성을 제공하는 하이브리드 모델을 만들었다. 우리는 이미 기존 광산 업체들로부터 관심을 받고 있지만, 특히 중요한 광물의 전략적 가치를 이해하는 새로운 투자자들을 이 분야에 끌어들이는 것에 대해 기대하고 있다.
<h4 class="wp-block-heading">중요 광물의 외국 공급원에 의존하는 것의 단점은 무엇인가요? </h4>
중국의 최근 움직임은 여기서 긴급성을 강조한다. 중국은 이미 게르마늄과 갈륨에 대한 수출 통제를 시행했고, 최근 안티모니도 목록에 추가했다. 이는 더 이상 이론적인 문제가 아니라, 실제로 발생하고 있다. 우리는 방산 및 기술에 필수적인 이러한 광물에 대해 공급망의 지역적 회복력을 구축해야 한다. 다윈 광산은 단일 자산에서 여러 중요한 광물의 국내 공급원을 구축할 수 있는 독특한 기회를 제공한다. 이는 찾기 어려운 일이다.
<h4 class="wp-block-heading">광산은 태양열로 운영되나요? </h4>
100MW 시설은 광산만을 전력 공급하는 것이 아니라, 우리가 생산하는 광물로 발전소 규모의 에너지 저장 시스템을 개발할 수 있는 충분한 청정 에너지를 생성할 것이다. 이는 우리의 광산 운영이 청정 에너지 배치를 직접 지원하는 선순환을 만든다.
<h4 class="wp-block-heading">2025년 목표는 무엇인가요? </h4>
2025년의 주요 목표는 자금 지원 후 6개월 이내에 황화물 생산을 하루 300톤으로, 9개월 이내에 산화물 생산을 하루 200톤으로 끌어올리는 것이다. 이는 월 1,000만 달러의 매출을 달성하게 되며, 그 후 심화된 광산 개발 프로그램이 발동다.
지난 주의 거래 소식은 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%89%98-%EC%9C%A0%EB%8B%88%EB%A0%88%EB%B2%84-%EC%99%B8%EC%97%90%EB%8F%84-%EB%A7%A4%EA%B0%81-%EB%89%B4%EC%8A%A4-%EC%96%B4%EB%8B%88%EC%96%B8%EC%9D%B4/" target="_blank" rel="noopener">여기를 클릭하세요</a>.
지금 읽을 내용: 
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/ai-%EB%AC%BC%EA%B2%B0%EC%9D%84-%ED%83%80%EA%B3%A0-%EC%97%94%EB%B9%84%EB%94%94%EC%95%84%EA%B0%80-%EB%8B%A4%EC%9A%B0%EC%A1%B4%EC%8A%A4-%EC%82%B0%EC%97%85%ED%8F%89%EA%B7%A0-%EC%A7%80%EC%88%98%EC%97%90/" target="_blank" rel="noopener">엔비디아, AI 붐으로 인텔을 다우존스 산업평균지수에서 교체하여 25년간의 지배를 종료</a></li>
</ul>
이미지: Benzinga
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Exclusives

Interview

AMCR

BERY

BMWYY

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

딜 디스패치: 스타벅스 중국 사업 매각 고려, 노스볼트 파산, 다윈 파이낸셜이 광업에 대해 논의

<h3 class="wp-block-heading">새로 등장한 블록</h3>
에볼런트 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/evh" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for EVH">EVH</a>)가 <a href="https://www.benzinga.com/m-a/24/08/40529349/evolent-health-explores-sale-garners-inbound-interest-from-private-equity-firms" target="_blank" rel="noopener" data-google-interstitial="false">매물로 나온 것</a>으로 알려졌다. 버지니아 주 알링턴에 본사를 둔 이 소프트웨어 회사는 인수 문의를 받은 후 경매 프로세스를 시작했다. 잠재적인 구혼자 중에는 TPG(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/tpg" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TPG">TPG</a>), 클레이톤, 듀블리에 &amp; 라이스(Clayton, Dubilier &amp; Rice), KKR &amp; 컴퍼니(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kkr" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KKR">KKR</a>)가 있다. 로이터는 건강 보험사 엘레반스 헬스(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/elv" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ELV">ELV</a>)가 한 사모 펀드 파트너와 협력하여 거래를 추진할 수 있다고 보고했다.
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">암 치료제 개발에 주력하는 기업인 크로노스 바이오(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/kron" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for KRON">KRON</a>)가 인수나 합병 등 &#8216;전략적 대안&#8217;을 모색하고 있다. 캘리포니아주 샌머테이오에 본사를 둔 크로노스 바이오는 9월 30일 현재 1억 2,490만 달러의 현금 보유고를 보고했다.</div>
<div>
생고뱅(OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codgf" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODGF">CODGF</a>) (OTCPK:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/codyy" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CODYY">CODYY</a>)은 <a href="https://www.bloomberg.com/news/articles/2024-11-13/st-gobain-is-said-to-weigh-2-5-billion-sale-of-auto-glass-unit" target="_blank" rel="noopener">블룸버그</a>에 따르면 최대 25억 유로(26억 달러)에 달하는 자동차 유리 사업부 매각을 고려하고 있다. 이 회사는 광범위한 비즈니스 평가의 일환으로 이러한 전략적 움직임을 고려하고 있는 것으로 알려졌다. 이번 매각은 운영을 간소화하고 핵심 사업 분야에 집중하려는 생고뱅(Saint-Gobain)의 노력과 일치한다.
쉘(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/shel" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SHEL" data-google-interstitial="false">SHEL</a>)은 탄소 상쇄 포트폴리오의 대부분을 <a href="https://www.bloomberg.com/news/articles/2024-11-13/shell-aims-to-sell-majority-stake-in-carbon-offsets-business?srnd=phx-deals" target="_blank" rel="noopener">폐기하려고</a> 한다. 이 회사는 <a href="https://www.bloomberg.com/news/features/2023-08-31/shell-silently-abandoned-its-100-million-a-year-plan-to-offset-co2-emissions" target="_blank" rel="noreferrer noopener">2018</a>년에 수십 개의 프로젝트를 포괄하는 오프셋 포트폴리오를 처음 출시했다.
</div>
유니레버(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UL#NYSE">UL</a>)는 우녹스(Unox) 수프, 코니멕스(Conimex) 조미료 등 일부 네덜란드 식품 브랜드의 판매를 모색하고 있다. 로이터에 따르면 회사는 대신 자사의 가장 큰 &#8216;파워&#8217; 라벨에 집중할 것이라고 한다.
<h3 class="wp-block-heading">파산 블록</h3>
알렉스 존스(Alex Jones)의 미디어 회사인 인포워스(Infowars)가 디 어니언(The Onion)에 인수되었다는 소식이다. 이 거래의 뒷받침은 <a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">샌디 훅(</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">Sandy Hook</a><a href="https://www.benzinga.com/media/24/11/41982446/jokes-on-jones-onion-backed-by-families-of-sandy-hook-victims-buys-info-wars" target="_blank" rel="noopener" data-google-interstitial="false">) 피해자</a> 가족들로, 이들은 존스가 10억 달러 이상의 명예훼손 판결을 지고 있는 상황에서 이 거래를 시가에 상징적 정의라고 찬양했다. 일론 머스크 및 터커 칼슨 등 우파 인사들의 <a href="https://www.benzinga.com/news/23/12/36168941/elon-musks-controversial-move-alex-jones-returns-to-x-after-user-vote" target="_blank" rel="noopener" data-google-interstitial="false">동정을 받아온</a> 존스는 눈에 띄게 괴로워하는 소셜 미디어 영상을 통해 &#8220;민주당&#8221;을 비난하며 인수를 확인했다.
다이아몬드 스포츠 그룹(Diamond Sports Group)의 구조 조정에는 부채를 약 90억 달러에서 2억 달러로 줄이는 것이 포함될 것이라고 <a href="https://www.espn.com/mlb/story/_/id/42388454/diamond-sports-group-emerges-bankruptcy" target="_blank" rel="noopener">ESPN</a>이 보도했다. 구조조정 계획은 다이아몬드가 부채 보유자들로부터 &#8220;거의 만장일치의 지지&#8221;로 분류한 것을 받았다. 현재 1억 달러의 유동성을 보유하고 있는 다이아몬드는 파산 상태에서 벗어나 독립 기업으로 운영될 예정이다. 모회사인 싱클레어(Sinclair)는 2019년에 폭스(Fox)로부터 지역 채널을 106억 달러에 인수하기 위해 80억 달러의 빚을 졌다. 그 빚은 다이아몬드의 파산에 기여했다.
<h3 class="wp-block-heading">블록의 업데이트</h3>
현재 휴마나(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/hum" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HUM" data-google-interstitial="false">HUM</a>)가 적극적으로 매각을 추진하고 있다는 구체적인 징후는 없다. 시그나 그룹(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ci" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for CI" data-google-interstitial="false">CI</a>)이 휴마나를 인수한다는 최근 추측이 확실하게 해결되었으며, 시그나는 현재로서는 휴마나와의 <a href="https://www.benzinga.com/general/health-care/24/11/41877573/cigna-not-pursuing-humana-merger-stock-soars" target="_blank" rel="noopener" data-google-interstitial="false">합병을 추진하지 않는다</a>고 명시적으로 밝혔다. 이러한 해명은 새로운 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">공화당 행정부와 의회</a> 하에서 보다 관대한 독점 금지 검토가 이루어질 가능성에 따라 선거 후 소문이 다시 불붙은 후에 나온 것이다.
스피릿 항공(NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/save" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for SAVE" data-google-interstitial="false">SAVE</a>)는 더 이상 프론티어 항공(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/ulcc" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for ULCC" data-google-interstitial="false">ULCC</a>)과 거래 협상을 진행하지 않는다. 현재 파산 계획을 확정하기 위해 채권 보유자와 사전 논의가 진행 중이다. 이 항공사는 계속해서 증가하는 손실과 다가오는 부채 만기 문제로 어려움을 겪고 있다. <a href="https://www.benzinga.com/news/earnings/24/11/41932146/spirit-airlines-nears-bankruptcy-creditors-may-approve-equity-cancellation-heres-what-it-means-for-investors-as-shares-fall-with-a-thud" target="_blank" rel="noopener" data-google-interstitial="false">월스트리트 저널</a>에 따르면 파산 신청은 몇 주 안에 이뤄질 것으로 예상된다.
<div class="ticker-wrapper">
<div class="sc-grPMMF hjTkfb ticker-box-wrapper">
메이 파마(NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/meip" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for MEIP" data-google-interstitial="false">MEIP</a>)는 계속해서 M&amp;A 기회를 모색하고 있으며 오펜하이머(Oppenheimer &amp; Co., Inc.)를 전담 재무 자문사로 고용하여 프로세스를 지원한다. 2025회계연도 1분기 동안 회사는 인력 감축을 포함한 현금 보존 노력을 시작했으며, 이는 회사의 운영 및 전략 방향이 발전함에 따라 단계적으로 계속될 것이다.
<h3 class="wp-block-heading">블록에서의 메모</h3>
월스트리트는 공화당이 의회를 장악하고 규제를 완화함에 따라 M&amp;A가 급증할 것으로 예상하고 있다. 분석가들은 리나 칸(Lina Khan) 연방거래위원회(FTC) 위원장의 해임으로 인해 독점 금지 조사가 쉬워질 것으로 예상하고 있다. 뱅크 오브 아메리카는 도널드 트럼프 대통령 당선자와 같은 공화당 행정부가 역사적으로 민주당 행정부에 비해 금융 부문 M&amp;A 활동을 50% 이상 육성했다는 점을 강조한다.
뱅크 오브 아메리카는 또한 금리 인하가 발효되고 경제 상황이 안정화됨에 따라 2025년은 M&amp;A에 있어 더 좋은 해가 될 수 있다고 예측한다. 다음은 은행이 수집한 5가지 잠재적 목표 목록이다. <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">전체 목록</a>을 보려면 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates" target="_blank" rel="noopener" data-google-interstitial="false">여기를 클릭</a>하세요.
<table class="block core-block table" style="height: 336px;" width="895">
<thead>
<tr>
<th>회사</th>
<th>섹터</th>
<th>시가 총액 ($M)</th>
<th>기업 가치 대비 잉여 현금 흐름 (%)</th>
<th>장기 성장 기대치 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>유니버셜 헬스 서비스 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/uhs" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for UHS" data-google-interstitial="false">UHS</a>)</td>
<td>헬스케어</td>
<td>13,932</td>
<td>4.4</td>
<td>25.3</td>
</tr>
<tr>
<td>랄프 로렌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/rl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for RL" data-google-interstitial="false">RL</a>)</td>
<td>소비재</td>
<td>12,473</td>
<td>5.99</td>
<td>10.5</td>
</tr>
<tr>
<td>파라마운트 글로벌 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/para" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for PARA" data-google-interstitial="false">PARA</a>)</td>
<td>통신 서비스</td>
<td>7,250</td>
<td>3.4</td>
<td>46.4</td>
</tr>
<tr>
<td>자빌 (NYSE:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/jbl" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for JBL" data-google-interstitial="false">JBL</a>)</td>
<td>기술</td>
<td>14,480</td>
<td>6.39</td>
<td>12.7</td>
</tr>
<tr>
<td>해즈브로 (NASDAQ:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/has" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for HAS" data-google-interstitial="false">HAS</a>)</td>
<td>소비재</td>
<td>9,215</td>
<td>3.6</td>
<td>27.5</td>
</tr>
</tbody>
</table>
</div>
</div>
지난주 딜 디스패치를 ​​보려면 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%94%9C-%EB%94%94%EC%8A%A4%ED%8C%A8%EC%B9%98-%EC%84%A0%EA%B1%B0-%EC%9D%B4%ED%9B%84-%EA%B5%90%EB%8F%84%EC%86%8C-%ED%9A%8C%EC%82%AC%EB%93%A4%EC%97%90-%EC%B4%88%EC%A0%90-%ED%8A%B8%EB%A6%BD%EC%96%B4/" target="_blank" rel="noopener">여기를 클릭</a>하세요.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

딜 디스패치: 쉘, 유니레버 외에도 매각 뉴스; 어니언이 알렉스 존스의 인포워스 인수 등

Comments

Humana

뉴스

에 대한 최신 뉴스 Humana (NYSE:HUM) 주식

수요일, 2월 12, 2025

월요일, 1월 13, 2025

금요일, 12월 20, 2024

토요일, 11월 23, 2024

일요일, 11월 17, 2024

월요일, 10월 21, 2024

일요일, 10월 06, 2024

수요일, 10월 02, 2024

일요일, 9월 15, 2024

화요일, 4월 02, 2024

금요일, 3월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌